A recent study reveals that patients who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who halt conventional diet and exercise programs.
Findings released in a major medical journal points out that while obese people can lose a large proportion of their total mass while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"People purchasing these drugs must be aware of the danger of fast weight regain when the therapy ends," stated expert Dr. Susan Jebb.
Such speed of recovery suggests a return to pre-treatment mass in about a year and a half.
Comparing Therapies
The analysis, which examined 37 of trials involving thousands of participants, compared the effects of GLP-1 agonists with other pills.
Scientists point out that individuals who shed pounds through lifestyle changes alone usually experience a less rapid creep back—around 100 grams monthly—post-intervention.
Explaining the Rapid Regain
Doctors suggest the mode of action of the jabs explains the amplified rebound.
GLP-1 drugs mimic a natural hormone called GLP-1, which controls hunger.
"Long-term administration of GLP-1 levels several times higher than normal may cause the system to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication results in appetite is uncontrolled, making excessive eating a significant risk."
A Lifelong Condition?
The NHS advise the injections for people with weight-linked health risks, alongside recommended lifestyle changes.
Many experts contend that, due to the significant potential of relapse, the treatment should be considered long-term.
This opinion is supported by drug manufacturers, who state that the results "highlight the persistent character of obesity," comparing it to managing conditions like diabetes.
User Accounts
Users who have come off the medication report a intense return of appetite.
"It felt as if a switch that goes on and I was suddenly extremely hungry," recalled an individual.
This difficulty is worsened if patients have not established permanent dietary or behavioural changes during treatment.
Growing Use
Figures suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is more common among women compared to males.
- The middle-aged age group shows the highest usage rates.
- Many obtain the medications through private healthcare rather than public health services.
Finally, experts emphasize that while these medications are powerful agents for weight loss, they are not a permanent solution and maintained weight loss hinges on ongoing behavioural support.
